Health news round-up: vaccination, testosterone and neighbourhood health The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
‘Stark lack of government response’ on valproate redress, patient safety commissioner says In her annual report for 2025/2026, Henrietta Hughes said the government was “yet to announce a redress scheme or a timeline for providing a substantive response to the recommendations” made in her previous report on patients harmed by sodium valproate.…
Everything you need to know about GLP-1s for weight loss From semaglutide to tirzepatide, this article collates the latest information on pharmacological weight-loss treatments, including evidence and best practice for their use.…
Call to reclassify morning-after pill as general sales list item The College of Sexual and Reproductive Healthcare has called for emergency hormonal contraception to be sold in shops alongside condoms and pregnancy tests to increase women's autonomy over their reproductive health.…
Postpartum reintegration: an uncomfortable silence pharmacy can no longer afford The pharmacy sector must practice what it preaches by providing adequate support to mothers returning to work.…
In vitro fertilisation: eligibility, processes and technologies An overview of the IVF process while considering the modifiable lifestyle factors that can optimise fertility and need for effective patient counselling and support.…
Oral hormonal contraception: a practical guide A practical, evidence-based overview of oral hormonal contraception, with a focus on eligibility assessment, initiation and monitoring.…
NICE recommends specific ‘artificial pancreas’ for pregnant women with type 1 diabetes The National Institute for Health and Care Excellence said that clinicians should offer training and support with hybrid closed systems for women with type 1 diabetes who are pregnant or planning a pregnancy.…
UK government rules out appointment of valproate tsar Health minister Preet Kaur Gill confirmed in a parliamentary answer that the Department of Health and Social Care “does not at present intend to appoint a senior team or a tsar in relation to those affected by sodium valproate”.…
No increased risk of neurodevelopmental disorders in children of fathers using valproate In a review of previous studies, researchers examined the paternal use of valproate with lamotrigine or levetiracetam and their effects on offspring.…
